MARKET

OLMA

OLMA

Olema Pharmaceuticals, Inc.
NASDAQ
25.36
+0.35
+1.40%
After Hours: 24.87 -0.49 -1.93% 18:42 02/06 EST
OPEN
25.57
PREV CLOSE
25.01
HIGH
26.48
LOW
25.24
VOLUME
962.29K
TURNOVER
--
52 WEEK HIGH
36.26
52 WEEK LOW
2.860
MARKET CAP
1.99B
P/E (TTM)
-14.0467
1D
5D
1M
3M
1Y
5Y
1D
Olema Pharmaceuticals to Join Major Biotech and Oncology Investor Conferences
Reuters · 2d ago
Olema Pharmaceuticals Grants Stock Options to New Employees Under Inducement Plan
Reuters · 3d ago
OLEMA ONCOLOGY REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 3d ago
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Barchart · 3d ago
The Bull Case For Olema Pharmaceuticals (OLMA) Could Change Following CFO Exit Amid Palazestrant Phase 3 Focus
Simply Wall St · 3d ago
Analysts Offer Insights on Healthcare Companies: Olema Pharmaceuticals (OLMA) and Maze Therapeutics, Inc. (MAZE)
TipRanks · 4d ago
Weekly Report: what happened at OLMA last week (0126-0130)?
Weekly Report · 5d ago
A Look At Olema Pharmaceuticals (OLMA) Valuation After Renewed Buy Ratings And Phase 3 Breast Cancer Plans
Simply Wall St · 5d ago
More
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.

Webull offers Olema Pharmaceuticals Inc stock information, including NASDAQ: OLMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OLMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OLMA stock methods without spending real money on the virtual paper trading platform.